Metal–Organic Framework Encapsulated Whole-Cell Vaccines Enhance Humoral Immunity against Bacterial Infection

The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:ACS nano Ročník 15; číslo 11; s. 17426 - 17438
Hlavní autori: Luzuriaga, Michael A, Herbert, Fabian C, Brohlin, Olivia R, Gadhvi, Jashkaran, Howlett, Thomas, Shahrivarkevishahi, Arezoo, Wijesundara, Yalini H, Venkitapathi, Sundharamani, Veera, Kavya, Ehrman, Ryanne, Benjamin, Candace E, Popal, Sarah, Burton, Michael D, Ingersoll, Molly A, De Nisco, Nicole J, Gassensmith, Jeremiah J
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Chemical Society 23.11.2021
Predmet:
Animals
Antigens
Bacterial Infections
Escherichia coli
Immunity, Humoral
Immunology
Life Sciences
Metal-Organic Frameworks
Mice
Vaccination - methods
Vaccines
whole cell vaccine
vaccine
germinal center
MOF
E. coli
urinary tract infection
ISSN:1936-0851, 1936-086X, 1936-086X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many potential target antigens and little a priori knowledge of which antigen/s will elicit protective immunity. The painstaking process of selecting appropriate antigens could be avoided with whole-cell bacteria; however, whole-cell formulations typically fail to produce long-term and durable immune responses. These complications are one reason why no vaccine against any type of pathogenic E. coli has been successfully clinically translated. As a proof of principle, we demonstrate a method to enhance the immunogenicity of a model pathogenic E. coli strain by forming a slow releasing depot. The E. coli strain CFT073 was biomimetically mineralized within a metal–organic framework (MOF). This process encapsulates the bacteria within 30 min in water and at ambient temperatures. Vaccination with this formulation substantially enhances antibody production and results in significantly enhanced survival in a mouse model of bacteremia compared to standard inactivated formulations.
AbstractList The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many potential target antigens and little a priori knowledge of which antigen/s will elicit protective immunity. The painstaking process of selecting appropriate antigens could be avoided with whole-cell bacteria; however, whole-cell formulations typically fail to produce long-term and durable immune responses. These complications are one reason why no vaccine against any type of pathogenic E. coli has been successfully clinically translated. As a proof of principle, we demonstrate a method to enhance the immunogenicity of a model pathogenic E. coli strain by forming a slow releasing depot. The E. coli strain CFT073 was biomimetically mineralized within a metal–organic framework (MOF). This process encapsulates the bacteria within 30 min in water and at ambient temperatures. Vaccination with this formulation substantially enhances antibody production and results in significantly enhanced survival in a mouse model of bacteremia compared to standard inactivated formulations.
The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many potential target antigens and little a priori knowledge of which antigen/s will elicit protective immunity. The painstaking process of selecting appropriate antigens could be avoided with whole-cell bacteria; however, whole-cell formulations typically fail to produce long-term and durable immune responses. These complications are one reason why no vaccine against any type of pathogenic E. coli has been successfully clinically translated. As a proof of principle, we demonstrate a method to enhance the immunogenicity of a model pathogenic E. coli strain by forming a slow releasing depot. The E. coli strain CFT073 was biomimetically mineralized within a metal-organic framework (MOF). This process encapsulates the bacteria within 30 min in water and at ambient temperatures. Vaccination with this formulation substantially enhances antibody production and results in significantly enhanced survival in a mouse model of bacteremia compared to standard inactivated formulations.The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many potential target antigens and little a priori knowledge of which antigen/s will elicit protective immunity. The painstaking process of selecting appropriate antigens could be avoided with whole-cell bacteria; however, whole-cell formulations typically fail to produce long-term and durable immune responses. These complications are one reason why no vaccine against any type of pathogenic E. coli has been successfully clinically translated. As a proof of principle, we demonstrate a method to enhance the immunogenicity of a model pathogenic E. coli strain by forming a slow releasing depot. The E. coli strain CFT073 was biomimetically mineralized within a metal-organic framework (MOF). This process encapsulates the bacteria within 30 min in water and at ambient temperatures. Vaccination with this formulation substantially enhances antibody production and results in significantly enhanced survival in a mouse model of bacteremia compared to standard inactivated formulations.
The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The development of vaccines against pathogenic bacteria has been difficult owing, in part, to the genetic diversity of bacteria. Hence, there are many potential target antigens and little knowledge of which antigen/s will elicit protective immunity. The painstaking process of selecting appropriate antigens could be avoided with whole-cell bacteria; however, whole-cell formulations typically fail to produce long-term and durable immune responses. These complications are one reason why no vaccine against any type of pathogenic has been successfully clinically translated. As a proof of principle, we demonstrate a method to enhance the immunogenicity of a model pathogenic strain by forming a slow releasing depot. The strain CFT073 was biomimetically mineralized within a metal-organic framework (MOF). This process encapsulates the bacteria within 30 min in water and at ambient temperatures. Vaccination with this formulation substantially enhances antibody production and results in significantly enhanced survival in a mouse model of bacteremia compared to standard inactivated formulations.
Author Benjamin, Candace E
De Nisco, Nicole J
Gassensmith, Jeremiah J
Veera, Kavya
Burton, Michael D
Herbert, Fabian C
Venkitapathi, Sundharamani
Shahrivarkevishahi, Arezoo
Ehrman, Ryanne
Popal, Sarah
Ingersoll, Molly A
Gadhvi, Jashkaran
Wijesundara, Yalini H
Brohlin, Olivia R
Luzuriaga, Michael A
Howlett, Thomas
AuthorAffiliation School of Brain and Behavioral Science
Department of Chemistry and Biochemistry
Department of Immunology
Department of Biological Sciences
Department of Biomedical Engineering
AuthorAffiliation_xml – name: School of Brain and Behavioral Science
– name: Department of Immunology
– name: Department of Biomedical Engineering
– name: Department of Biological Sciences
– name: Department of Chemistry and Biochemistry
Author_xml – sequence: 1
  givenname: Michael A
  orcidid: 0000-0001-6128-8800
  surname: Luzuriaga
  fullname: Luzuriaga, Michael A
– sequence: 2
  givenname: Fabian C
  surname: Herbert
  fullname: Herbert, Fabian C
– sequence: 3
  givenname: Olivia R
  orcidid: 0000-0003-3226-6711
  surname: Brohlin
  fullname: Brohlin, Olivia R
– sequence: 4
  givenname: Jashkaran
  surname: Gadhvi
  fullname: Gadhvi, Jashkaran
– sequence: 5
  givenname: Thomas
  surname: Howlett
  fullname: Howlett, Thomas
– sequence: 6
  givenname: Arezoo
  surname: Shahrivarkevishahi
  fullname: Shahrivarkevishahi, Arezoo
– sequence: 7
  givenname: Yalini H
  surname: Wijesundara
  fullname: Wijesundara, Yalini H
– sequence: 8
  givenname: Sundharamani
  surname: Venkitapathi
  fullname: Venkitapathi, Sundharamani
– sequence: 9
  givenname: Kavya
  surname: Veera
  fullname: Veera, Kavya
– sequence: 10
  givenname: Ryanne
  surname: Ehrman
  fullname: Ehrman, Ryanne
– sequence: 11
  givenname: Candace E
  surname: Benjamin
  fullname: Benjamin, Candace E
– sequence: 12
  givenname: Sarah
  surname: Popal
  fullname: Popal, Sarah
– sequence: 13
  givenname: Michael D
  surname: Burton
  fullname: Burton, Michael D
– sequence: 14
  givenname: Molly A
  surname: Ingersoll
  fullname: Ingersoll, Molly A
  organization: Department of Immunology
– sequence: 15
  givenname: Nicole J
  orcidid: 0000-0002-7670-5301
  surname: De Nisco
  fullname: De Nisco, Nicole J
  email: Nicole.DeNisco@UTDallas.edu
– sequence: 16
  givenname: Jeremiah J
  orcidid: 0000-0001-6400-8106
  surname: Gassensmith
  fullname: Gassensmith, Jeremiah J
  email: Gassensmith@utdallas.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34546723$$D View this record in MEDLINE/PubMed
https://pasteur.hal.science/pasteur-03375261$$DView record in HAL
BookMark eNp9kc1uEzEUhS1U1P81OzRLpGpaezwex8sStaRSUDdQ2Fl3_NO4eOxge0Dd8Q68IU_CRAlZIMHqXul-50j3nBN0EGIwCL0i-JLghlyBygFCvCQKUyyaF-iYCNrVeNZ9PtjvjByhk5yfMGZ8xrtDdERb1na8occovjcF_K8fP-_TIwSnqtsEg_ke05fqJihY59FDMbr6tIre1HPjffUASrlg8gSsIChTLcYhJvDV3TCMwZXnCh7BhVyqt6CKSW5zCtao4mI4Qy8t-GzOd_MUfby9-TBf1Mv7d3fz62UNLWlK3RKh-74XLSiKFdas162AXotu1itre8GVZpaTjlsQAJZOnzFtraEtBc04PUX11ncFXq6TGyA9ywhOLq6Xcg25mDFJTClnTUe-kYl_s-XXKX4dTS5ycFlN70IwccyyYZxRwUVDJ_T1Dh37wei9-59QJ-BqC6gUc07G7hGC5aY2uatN7mqbFOwvhXIFNnmVBM7_R3ex1U0H-RTHFKZM_0n_BgL7r6o
CitedBy_id crossref_primary_10_1016_j_cej_2025_168227
crossref_primary_10_1002_ange_202413020
crossref_primary_10_1186_s12951_024_02853_2
crossref_primary_10_1002_smll_202204011
crossref_primary_10_1007_s12598_023_02450_6
crossref_primary_10_1631_bdm_2300327
crossref_primary_10_1039_D4SC05680A
crossref_primary_10_1002_adtp_202300037
crossref_primary_10_1039_D2CC03072A
crossref_primary_10_1002_adhm_202402358
crossref_primary_10_1016_j_biomaterials_2024_123060
crossref_primary_10_1016_j_nantod_2023_101803
crossref_primary_10_1016_j_addr_2024_115316
crossref_primary_10_1039_D3SC06734C
crossref_primary_10_3390_vaccines12050535
crossref_primary_10_1016_j_bbagen_2024_130558
crossref_primary_10_1039_D4RA00545G
crossref_primary_10_3389_fimmu_2025_1641997
crossref_primary_10_1002_adfm_202504465
crossref_primary_10_1002_anie_202413020
crossref_primary_10_1080_19490976_2024_2359691
crossref_primary_10_1021_acsabm_4c01398
crossref_primary_10_1039_D3SC00500C
crossref_primary_10_1016_j_tibtech_2022_01_012
crossref_primary_10_1002_wnan_1877
crossref_primary_10_3390_vaccines10050751
crossref_primary_10_1002_smsc_202400432
crossref_primary_10_1021_acs_chemrev_4c00984
crossref_primary_10_1016_j_matt_2023_06_002
crossref_primary_10_1038_s41467_024_52489_x
crossref_primary_10_1073_pnas_2218247120
crossref_primary_10_1002_adfm_202308589
crossref_primary_10_1002_adfm_202501307
crossref_primary_10_1002_sstr_202200346
crossref_primary_10_1016_j_jcis_2022_12_020
crossref_primary_10_1016_j_pmatsci_2025_101532
crossref_primary_10_1016_j_xcrm_2025_102092
crossref_primary_10_1039_D3BM00306J
crossref_primary_10_1016_j_cej_2025_160179
crossref_primary_10_1039_D2SC04982A
crossref_primary_10_1016_j_micpath_2021_105295
crossref_primary_10_1128_iai_00440_23
Cites_doi 10.1016/j.apmt.2017.12.014
10.1021/ac048144+
10.1128/iai.63.12.4619-4627.1995
10.1101/cshperspect.a016295
10.3390/pathogens5010001
10.3109/08982104.2015.1029494
10.1016/j.ucl.2007.09.010
10.1039/9781849735643-00056
10.1038/nchembio.1382
10.1021/acsnano.7b08056
10.1039/c2ra21087h
10.1021/jacs.8b04457
10.1021/acs.chemmater.7b04713
10.1111/bju.14606
10.1067/mda.2003.7
10.1021/bk-2018-1298.ch006
10.1128/mBio.00262-10
10.1021/acs.bioconjchem.0c00190
10.1073/pnas.0915077107
10.1038/s41598-018-24964-1
10.1016/j.vaccine.2015.12.014
10.1016/j.biomaterials.2012.03.041
10.1021/acsnano.5b01426
10.1002/adfm.201504998
10.1016/0166-0934(91)90036-Y
10.1142/10573
10.1371/journal.ppat.1002357
10.1021/bm301278f
10.1002/mabi.201800362
10.1016/S0264-410X(00)00354-6
10.1021/acscentsci.0c00732
10.3390/vaccines3040940
10.1371/journal.pone.0029585
10.1021/mp500675p
10.1080/14728214.2017.1293650
10.1097/CCM.0b013e318250aa72
10.1128/iai.38.1.21-26.1982
10.1128/microbiolspec.UTI-0013-2012
10.1016/j.vaccine.2017.01.030
10.1021/acsami.9b15667
10.1371/journal.ppat.1000586
10.1016/j.ijpharm.2017.09.043
10.1021/acsami.8b20504
10.1002/pro.3215
10.1002/adfm.201600650
10.1016/j.jconrel.2019.02.035
10.1002/bip.20689
10.1021/acs.molpharmaceut.8b01185
10.1128/mBio.00218-20
10.1016/j.immuni.2007.02.011
10.1073/pnas.252529799
10.1039/B611918M
10.1021/acsnano.7b02786
10.1038/ncomms8240
10.1007/82_2018_111
10.1128/microbiolspec.UTI-0024-2016
10.4161/bbug.1.5.12540
10.1002/adma.201706785
10.1002/adma.201602335
10.1172/JCI68964
10.1002/adma.201604433
10.1073/pnas.0707331104
10.1186/s12879-016-1496-0
10.1039/c2dt30357d
10.1016/S0924-8579(00)00350-2
10.1016/j.jcrc.2009.12.004
10.1128/IAI.05621-11
10.1021/acs.biomac.7b00537
10.1096/fj.202000760R
10.1128/iai.22.3.790-797.1978
10.1016/S0168-3659(02)00267-5
10.1016/j.jconrel.2006.06.014
10.1038/s41467-021-22285-y
10.3390/ijms21020510
10.1038/nrmicro818
10.3389/fimmu.2013.00114
10.1086/317537
10.1016/j.vaccine.2006.11.058
10.1039/C4CS00089G
10.1117/1.JBO.20.5.051008
10.7257/1053-816X.2015.35.4.191
10.1016/j.jconrel.2018.01.027
10.1021/acs.bioconjchem.8b00483
10.1080/10610278.2019.1616089
10.4049/jimmunol.0902386
10.1097/01.ju.0000075094.54767.6e
10.1073/pnas.1902179116
10.1016/j.carres.2003.07.008
10.1016/j.colsurfb.2018.04.033
10.1016/j.jconrel.2018.09.020
10.1002/adhm.201800950
10.1039/C5BM00451A
10.1002/adma.201200776
10.1002/adbi.201700176
10.1016/0264-410X(94)90293-3
10.1021/jacs.6b03673
10.1073/pnas.1606050113
10.1080/21645515.2015.1117714
10.1111/j.1365-2621.2002.tb10310.x
10.3389/fmicb.2017.01566
10.1007/978-3-642-54859-8_32
10.1002/anie.202000678
10.3390/pharmaceutics11050221
10.1073/pnas.0602439103
10.1021/acsami.8b01369
10.7150/thno.18879
10.3389/fimmu.2018.01657
10.1038/s41585-020-0350-8
10.1172/jci.insight.122998
10.3390/antibiotics5030031
ContentType Journal Article
Copyright 2021 American Chemical Society
licence_http://creativecommons.org/publicdomain/zero
Copyright_xml – notice: 2021 American Chemical Society
– notice: licence_http://creativecommons.org/publicdomain/zero
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
1XC
DOI 10.1021/acsnano.1c03092
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Hyper Article en Ligne (HAL)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1936-086X
EndPage 17438
ExternalDocumentID oai:HAL:pasteur-03375261v1
34546723
10_1021_acsnano_1c03092
i62145349
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
23M
4.4
55A
5GY
5VS
7~N
AABXI
ABFRP
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
EBS
ED
F5P
GGK
GNL
IH9
IHE
JG
K2
P2P
RNS
ROL
UI2
VF5
VG9
W1F
XKZ
YZZ
---
.K2
6J9
AAHBH
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ACBEA
ACGFO
ADHGD
ADHLV
BAANH
CITATION
CUPRZ
ED~
JG~
CGR
CUY
CVF
ECM
EIF
NPM
7X8
1XC
ID FETCH-LOGICAL-a412t-419dbbb94ac30c0d5bd49abd968bcffb97cd5f7167fa9aaf35785dffe343ad573
IEDL.DBID ACS
ISICitedReferencesCount 59
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000747115200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1936-0851
1936-086X
IngestDate Fri Nov 14 06:20:51 EST 2025
Fri Jul 11 15:12:00 EDT 2025
Thu Apr 03 07:03:38 EDT 2025
Sat Nov 29 05:41:37 EST 2025
Tue Nov 18 22:22:34 EST 2025
Thu Nov 25 03:13:29 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords whole cell vaccine
vaccine
germinal center
MOF
E. coli
urinary tract infection
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
licence_http://creativecommons.org/publicdomain/zero/: http://creativecommons.org/publicdomain/zero
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a412t-419dbbb94ac30c0d5bd49abd968bcffb97cd5f7167fa9aaf35785dffe343ad573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-3226-6711
0000-0002-7670-5301
0000-0001-6128-8800
0000-0001-6400-8106
0000-0002-6388-7003
OpenAccessLink https://www.biorxiv.org/content/biorxiv/early/2021/07/29/2020.06.14.148452.full.pdf
PMID 34546723
PQID 2575397923
PQPubID 23479
PageCount 13
ParticipantIDs hal_primary_oai_HAL_pasteur_03375261v1
proquest_miscellaneous_2575397923
pubmed_primary_34546723
crossref_primary_10_1021_acsnano_1c03092
crossref_citationtrail_10_1021_acsnano_1c03092
acs_journals_10_1021_acsnano_1c03092
PublicationCentury 2000
PublicationDate 2021-11-23
PublicationDateYYYYMMDD 2021-11-23
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-23
  day: 23
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle ACS nano
PublicationTitleAlternate ACS Nano
PublicationYear 2021
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref45/cit45
ref99/cit99
ref3/cit3
ref81/cit81
ref16/cit16
ref52/cit52
ref23/cit23
ref110/cit110
ref111/cit111
ref77/cit77
ref71/cit71
ref20/cit20
ref48/cit48
ref74/cit74
ref10/cit10
ref35/cit35
ref89/cit89
ref19/cit19
ref93/cit93
ref42/cit42
ref96/cit96
ref107/cit107
ref109/cit109
ref13/cit13
ref105/cit105
ref61/cit61
ref67/cit67
ref38/cit38
ref90/cit90
ref64/cit64
ref54/cit54
ref6/cit6
ref65/cit65
ref97/cit97
ref101/cit101
ref11/cit11
ref102/cit102
ref29/cit29
ref76/cit76
ref86/cit86
Kabbani M. (ref2/cit2) 2014
ref32/cit32
ref39/cit39
ref5/cit5
ref43/cit43
ref80/cit80
ref28/cit28
ref91/cit91
ref55/cit55
ref12/cit12
ref66/cit66
ref22/cit22
ref33/cit33
ref87/cit87
ref106/cit106
ref44/cit44
ref70/cit70
ref98/cit98
ref9/cit9
ref27/cit27
ref63/cit63
ref56/cit56
ref92/cit92
ref8/cit8
ref31/cit31
ref59/cit59
ref85/cit85
ref34/cit34
ref37/cit37
ref60/cit60
ref88/cit88
ref17/cit17
ref82/cit82
Jones C. (ref30/cit30) 2012
ref53/cit53
ref21/cit21
ref49/cit49
ref75/cit75
ref24/cit24
ref50/cit50
ref78/cit78
ref36/cit36
ref83/cit83
ref79/cit79
ref100/cit100
ref25/cit25
ref103/cit103
ref72/cit72
ref14/cit14
ref57/cit57
ref51/cit51
Nesta B. (ref18/cit18) 2018
ref40/cit40
ref68/cit68
ref94/cit94
ref26/cit26
ref73/cit73
ref69/cit69
ref15/cit15
ref62/cit62
ref41/cit41
ref58/cit58
ref95/cit95
ref108/cit108
ref104/cit104
Karathanasis E. (ref46/cit46) 2007; 2
ref4/cit4
ref47/cit47
ref84/cit84
ref1/cit1
ref7/cit7
References_xml – ident: ref91/cit91
  doi: 10.1016/j.apmt.2017.12.014
– ident: ref53/cit53
  doi: 10.1021/ac048144+
– ident: ref80/cit80
  doi: 10.1128/iai.63.12.4619-4627.1995
– ident: ref90/cit90
  doi: 10.1101/cshperspect.a016295
– ident: ref24/cit24
  doi: 10.3390/pathogens5010001
– ident: ref44/cit44
  doi: 10.3109/08982104.2015.1029494
– ident: ref6/cit6
  doi: 10.1016/j.ucl.2007.09.010
– start-page: 56
  volume-title: Stability of complex carbohydrate structures: Biofuels, Food, Vaccines, and Shipwrecks
  year: 2012
  ident: ref30/cit30
  doi: 10.1039/9781849735643-00056
– ident: ref82/cit82
  doi: 10.1038/nchembio.1382
– ident: ref72/cit72
  doi: 10.1021/acsnano.7b08056
– ident: ref76/cit76
  doi: 10.1039/c2ra21087h
– ident: ref96/cit96
  doi: 10.1021/jacs.8b04457
– ident: ref66/cit66
  doi: 10.1021/acs.chemmater.7b04713
– ident: ref27/cit27
  doi: 10.1111/bju.14606
– ident: ref4/cit4
  doi: 10.1067/mda.2003.7
– ident: ref49/cit49
  doi: 10.1021/bk-2018-1298.ch006
– ident: ref110/cit110
  doi: 10.1128/mBio.00262-10
– ident: ref88/cit88
  doi: 10.1021/acs.bioconjchem.0c00190
– ident: ref23/cit23
  doi: 10.1073/pnas.0915077107
– ident: ref83/cit83
  doi: 10.1038/s41598-018-24964-1
– ident: ref12/cit12
  doi: 10.1016/j.vaccine.2015.12.014
– ident: ref104/cit104
  doi: 10.1016/j.biomaterials.2012.03.041
– ident: ref51/cit51
  doi: 10.1021/acsnano.5b01426
– ident: ref92/cit92
  doi: 10.1002/adfm.201504998
– ident: ref32/cit32
  doi: 10.1016/0166-0934(91)90036-Y
– ident: ref1/cit1
  doi: 10.1142/10573
– ident: ref84/cit84
  doi: 10.1371/journal.ppat.1002357
– ident: ref56/cit56
  doi: 10.1021/bm301278f
– ident: ref58/cit58
  doi: 10.1002/mabi.201800362
– ident: ref15/cit15
  doi: 10.1016/S0264-410X(00)00354-6
– ident: ref95/cit95
  doi: 10.1021/acscentsci.0c00732
– ident: ref16/cit16
  doi: 10.3390/vaccines3040940
– ident: ref45/cit45
  doi: 10.1371/journal.pone.0029585
– ident: ref57/cit57
  doi: 10.1021/mp500675p
– ident: ref10/cit10
  doi: 10.1080/14728214.2017.1293650
– ident: ref14/cit14
  doi: 10.1097/CCM.0b013e318250aa72
– ident: ref28/cit28
  doi: 10.1128/iai.38.1.21-26.1982
– volume: 2
  start-page: 501
  year: 2007
  ident: ref46/cit46
  publication-title: Int. J. Nanomedicine
– ident: ref26/cit26
  doi: 10.1128/microbiolspec.UTI-0013-2012
– ident: ref87/cit87
  doi: 10.1016/j.vaccine.2017.01.030
– ident: ref74/cit74
  doi: 10.1021/acsami.9b15667
– ident: ref20/cit20
  doi: 10.1371/journal.ppat.1000586
– ident: ref43/cit43
  doi: 10.1016/j.ijpharm.2017.09.043
– ident: ref37/cit37
  doi: 10.1021/acsami.8b20504
– ident: ref55/cit55
  doi: 10.1002/pro.3215
– ident: ref67/cit67
  doi: 10.1002/adfm.201600650
– ident: ref99/cit99
  doi: 10.1016/j.jconrel.2019.02.035
– ident: ref102/cit102
  doi: 10.1002/bip.20689
– ident: ref98/cit98
  doi: 10.1021/acs.molpharmaceut.8b01185
– ident: ref5/cit5
  doi: 10.1128/mBio.00218-20
– ident: ref85/cit85
  doi: 10.1016/j.immuni.2007.02.011
– ident: ref22/cit22
  doi: 10.1073/pnas.252529799
– ident: ref61/cit61
  doi: 10.1039/B611918M
– ident: ref60/cit60
  doi: 10.1021/acsnano.7b02786
– ident: ref62/cit62
  doi: 10.1038/ncomms8240
– start-page: 213
  volume-title: Escherichia coli, a Versatile Pathogen
  year: 2018
  ident: ref18/cit18
  doi: 10.1007/82_2018_111
– ident: ref21/cit21
  doi: 10.1128/microbiolspec.UTI-0024-2016
– ident: ref29/cit29
  doi: 10.4161/bbug.1.5.12540
– ident: ref52/cit52
  doi: 10.1002/adma.201706785
– ident: ref71/cit71
  doi: 10.1002/adma.201602335
– ident: ref101/cit101
  doi: 10.1172/JCI68964
– ident: ref68/cit68
  doi: 10.1002/adma.201604433
– ident: ref103/cit103
  doi: 10.1073/pnas.0707331104
– ident: ref86/cit86
  doi: 10.1186/s12879-016-1496-0
– ident: ref97/cit97
  doi: 10.1039/c2dt30357d
– ident: ref11/cit11
  doi: 10.1016/S0924-8579(00)00350-2
– ident: ref13/cit13
  doi: 10.1016/j.jcrc.2009.12.004
– ident: ref78/cit78
  doi: 10.1128/IAI.05621-11
– ident: ref48/cit48
  doi: 10.1021/acs.biomac.7b00537
– ident: ref109/cit109
  doi: 10.1096/fj.202000760R
– ident: ref19/cit19
  doi: 10.1128/iai.22.3.790-797.1978
– ident: ref79/cit79
  doi: 10.1016/S0168-3659(02)00267-5
– ident: ref39/cit39
  doi: 10.1016/j.jconrel.2006.06.014
– ident: ref73/cit73
  doi: 10.1038/s41467-021-22285-y
– ident: ref100/cit100
  doi: 10.3390/ijms21020510
– ident: ref77/cit77
  doi: 10.1038/nrmicro818
– ident: ref36/cit36
  doi: 10.3389/fimmu.2013.00114
– ident: ref105/cit105
  doi: 10.1086/317537
– ident: ref34/cit34
  doi: 10.1016/j.vaccine.2006.11.058
– ident: ref75/cit75
  doi: 10.1039/C4CS00089G
– ident: ref33/cit33
  doi: 10.1117/1.JBO.20.5.051008
– ident: ref9/cit9
  doi: 10.7257/1053-816X.2015.35.4.191
– ident: ref41/cit41
  doi: 10.1016/j.jconrel.2018.01.027
– ident: ref89/cit89
  doi: 10.1021/acs.bioconjchem.8b00483
– ident: ref64/cit64
  doi: 10.1080/10610278.2019.1616089
– ident: ref108/cit108
  doi: 10.4049/jimmunol.0902386
– ident: ref25/cit25
  doi: 10.1097/01.ju.0000075094.54767.6e
– ident: ref93/cit93
  doi: 10.1073/pnas.1902179116
– ident: ref17/cit17
  doi: 10.1016/j.carres.2003.07.008
– ident: ref47/cit47
  doi: 10.1016/j.colsurfb.2018.04.033
– ident: ref40/cit40
  doi: 10.1016/j.jconrel.2018.09.020
– ident: ref65/cit65
  doi: 10.1002/adhm.201800950
– ident: ref42/cit42
  doi: 10.1039/C5BM00451A
– ident: ref50/cit50
  doi: 10.1002/adma.201200776
– ident: ref59/cit59
  doi: 10.1002/adbi.201700176
– ident: ref31/cit31
  doi: 10.1016/0264-410X(94)90293-3
– ident: ref69/cit69
  doi: 10.1021/jacs.6b03673
– ident: ref35/cit35
  doi: 10.1073/pnas.1606050113
– ident: ref94/cit94
  doi: 10.1080/21645515.2015.1117714
– ident: ref81/cit81
  doi: 10.1111/j.1365-2621.2002.tb10310.x
– ident: ref3/cit3
  doi: 10.3389/fmicb.2017.01566
– start-page: 157
  volume-title: Urology at a Glance
  year: 2014
  ident: ref2/cit2
  doi: 10.1007/978-3-642-54859-8_32
– ident: ref111/cit111
  doi: 10.1002/anie.202000678
– ident: ref54/cit54
  doi: 10.3390/pharmaceutics11050221
– ident: ref63/cit63
  doi: 10.1073/pnas.0602439103
– ident: ref70/cit70
  doi: 10.1021/acsami.8b01369
– ident: ref38/cit38
  doi: 10.7150/thno.18879
– ident: ref106/cit106
  doi: 10.3389/fimmu.2018.01657
– ident: ref7/cit7
  doi: 10.1038/s41585-020-0350-8
– ident: ref107/cit107
  doi: 10.1172/jci.insight.122998
– ident: ref8/cit8
  doi: 10.3390/antibiotics5030031
SSID ssj0057876
Score 2.5863128
Snippet The increasing rate of resistance of bacterial infection against antibiotics requires next generation approaches to fight potential pandemic spread. The...
SourceID hal
proquest
pubmed
crossref
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 17426
SubjectTerms Animals
Antigens
Bacterial Infections
Escherichia coli
Immunity, Humoral
Immunology
Life Sciences
Metal-Organic Frameworks
Mice
Vaccination - methods
Vaccines
Title Metal–Organic Framework Encapsulated Whole-Cell Vaccines Enhance Humoral Immunity against Bacterial Infection
URI http://dx.doi.org/10.1021/acsnano.1c03092
https://www.ncbi.nlm.nih.gov/pubmed/34546723
https://www.proquest.com/docview/2575397923
https://pasteur.hal.science/pasteur-03375261
Volume 15
WOSCitedRecordID wos000747115200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVABC
  databaseName: American Chemical Society Journals
  customDbUrl:
  eissn: 1936-086X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0057876
  issn: 1936-0851
  databaseCode: ACS
  dateStart: 20070801
  isFulltext: true
  titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals
  providerName: American Chemical Society
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELb64ACH8oZtS2WkCnFJ2dhxnByXVVdFggqJ196s8YtWWmWrzW6l3vgP_EN-CTNJdkupVoJzHCvxjD2f9c18w9hhxChZCLBJsJlPSJA8KVRukwJc32shlYW22YQ-PS3G4_LjtVj03wy-SN-AqyuopkepIzYAT9ttgSCXnHkw_LQ8dMnv8pZAxgsyooiVis-tCSgMufpGGNo8oyTIdQiziTSj-__xjQ_YTgcn-aC1_0O2EapH7N4fIoOP2fRDQID968fPtuzS8dEyH4sfVw7wljxBvOn5N-qUmwzDZMK_giO-vcYBZ-QVHI1Olfz8XVNNMr_i8B3OEVjyt63YMz3qsrqqJ-zL6Pjz8CTp2iwkkKViTjywt9aWGTjZRwsp67MSrC_zwroYbamdVxHvVTpCCRAbfRwfY5CZBK-0fMq2qmkVnjNeNIW-ubYALtPRFTmiK-k1qKDKNPM9dohLZbptUpuGARep6dbPdOvXY0dL4xjXSZVTx4zJ-hder164aFU61g99hdZejSJ17ZPBe3MBuKkWM9OXUiu8VV6mPfZy6RAGtxzxKFCF6aI2eMopokOF7LFnraes5pOZwtAj5O6__ekeuysoSSZNEyH32dZ8tggv2B13OT-vZwdsU4-Lg8bRfwPUyPrZ
linkProvider American Chemical Society
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3bbhMxEB2VggQ8lFuBlJuRKsTLlux6vd59DFGjVKQREgX6Zo1vtFK0qbJJJd74B_6wX9LxXgIIRYLXXdvatY89MzqeMwD7nqxknqCOnE5tFATJo1xkOsrR9K1MuNDYFJuQ02l-elp83IJ-lwtDH1HRSFVN4v9SF4jf0bMSy_lBbAIpQIfuTUHGNSB7MPzUnb0BflnDI1OcTM7EWsznrwGCNTLVH9boxlm4C7nJ0awNzuje_3_qfdhpnUs2aNDwALZc-RDu_iY5-Ajmx47c7asfP5skTMNG3e0sdlgapJh5Rt6nZV9D3dxo6GYz9gVNYN8ranAWMMIIAiGvnx3VuSXL7wy_4Tm5mex9I_0cXrV3vMpd-Dw6PBmOo7boQoRpnCwDK2y11kWKhvdpvYS2aYHaFlmujfe6kMYKT1GW9Fgg-lotx3rveMrRCskfw3Y5L91TYHmd9ptJjWhS6U2eka_FrUThRBGntgf7NFWq3TSVqvnwJFbt_Kl2_npw0K2RMq1weaifMdvc4e26w0Wj2bG56Rta9HWroLU9HkzUBdIWWy1Un3MpKMa8jHvwusOFog0YWBUs3XxVKTrzRCBHE96DJw1g1uPxVJAhSvjev_3pK7g9PjmeqMnR9MMzuJOE6zNxHCX8OWwvFyv3Am6Zy-V5tXhZo_4aM6QCZg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BQQgOPAukvBapQlxcYq_Xax_T0KgVJarEq7fV7ItWipwoTipx4z_wD_klnbE3URGKhLjauyt7d2ZnRt_MN4ztBrSSZQYm8SZ3CRGSJ6UsTFKC7TuVCWmgazahxuPy9LQ6iUVhVAuDH9HgSk0L4pNWz1yIDAPpO3xeQz3dSy0BA3jx3pBozkm6B8NPq_uXRLDosGSMldGhWBP6_LUAWSTb_GGRrp9RPuQmZ7M1OqN7__e599nd6GTyQScVD9g1Xz9kd65QDz5i048e3e7fP391xZiWj1ZZWvygtoCx8wS9UMe_Uf_cZOgnE_4VLKHwDQ44I1nhKApU38-P2hqTxQ8O3-Ec3U2-31FA06uY61Vvsy-jg8_DwyQ2X0ggT7MFocPOGFPlYEUfz00al1dgXFWUxoZgKmWdDBhtqQAVQGhZc1wIXuQCnFTiMduqp7V_ynjZlv8WygDYXAVbFuhzCadAelmlueuxXdwqHZWn0S0unqU67p-O-9dje6tz0jYSmFMfjcnmCW_XE2Ydd8fmoW_w4NejiHP7cHCsZ4CqtpzrvhBKYqx5kfbY65VsaFREQleg9tNlo_HukwSSZqLHnnRCs15P5BINUiZ2_u1PX7FbJ-9H-vho_OEZu51RFk2aJpl4zrYW86V_wW7ai8V5M3_ZCv4lZdgE4A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metal%E2%80%93Organic+Framework+Encapsulated+Whole-Cell+Vaccines+Enhance+Humoral+Immunity+against+Bacterial+Infection&rft.jtitle=ACS+nano&rft.au=Luzuriaga%2C+Michael+A&rft.au=Herbert%2C+Fabian+C&rft.au=Brohlin%2C+Olivia+R&rft.au=Gadhvi%2C+Jashkaran&rft.date=2021-11-23&rft.pub=American+Chemical+Society&rft.issn=1936-0851&rft.eissn=1936-086X&rft.volume=15&rft.issue=11&rft.spage=17426&rft.epage=17438&rft_id=info:doi/10.1021%2Facsnano.1c03092&rft.externalDocID=i62145349
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-0851&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-0851&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-0851&client=summon